Latest Breaking News On - Thierry merquiol - Page 1 : comparemela.com

Mar 14 2021 Read 559 Times Biopharmaceutical company CVasThera, specialising in therapies for cardiovascular and bowel pathologies, has secured €1.3 million ($1.6M) in its first funding round that will be used to finance the preclinical trials for its CVT120165 compound, a drug candidate in the treatment of Crohn s disease. Safety data is already available from phase I trials involving healthy volunteers, which were conducted in 2008 in another indication. The company plans to proceed directly to a pilot phase II trial with Crohn’s patients in 2022. The primary investor is OCSEED, a venture capital company supporting start-ups in the Occitanie region of France; working capital from the company’s founders, an investment loan from Bpifrance, funding from the Occitanie region and a contract with the countries Agence Nationale de la Recherch Agency, are also providing financial input.

Thierry merquiolAgence nationale de la recherch agencyBruno le grandபுருனோ லெ மாபெரும்